IDH2 and acute myeloid leukemia: IDH inhibitors combine synergistically with azacitidine, with preliminary findings of phase 2 studies supporting a potential role for azacitidine combinations with either enasidenib18 or ivosidenib70 in patients with newly diagnosed AML and IDH2 or IDH1 mutations, respectively.